FDA approves InnoPharma’s acetylcysteine inhalation solution

The FDA has approved InnoPharma’s ANDA for acetylcysteine solution. The New Jersey company has a deal with Fresenius Kabi USA to market acetylcysteine solution in the US, where there has been a shortage of the product. Bedford Laboratories recalled acetylcysteine solution earlier this year and American Regent/Luitpold has experienced recurring manufacturing problems.

According to the company, it will make acetylcysteine solution, 20% concentration in 30 ml vials, available within a few weeks.

Read the InnoPharma press release.

Share

published on

December 9-December 11: DDL 2026, Edinburgh, Scotland

April 27-30: RDD Europe 2027, Antibes, France

June 30: RespireX 2027, Boston, MA, USA